SCHEMBL6810337

SCHEMBL6810337

CC(=O)N[C@@H]1[C@@H](OCc2ccccc2)O[C@H](COC(=O)c2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.55
▸ LMNA P02545 3/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ NT5E P21589 1/20 0.46
▸ TP53 P04637 2/20 0.44
▸ MDM2 Q00987 2/20 0.44
▸ TACR2 P21452 1/20 0.42
▸ MDM4 O15151 1/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ HSP90AB1 P08238 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ SSTR1 P30872 1/20 0.41
▸ SSTR2 P30874 1/20 0.41
▸ SSTR4 P31391 1/20 0.41
▸ SSTR3 P32745 1/20 0.41
▸ SSTR5 P35346 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6810335 0.92 POLB (0.52) POLBLMNAKMT2AL3MBTL1SSTR1
SCHEMBL13031053 0.92 POLB (0.61) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL13031056 0.88 POLB (0.52) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL5840927 0.87 TP53 (0.55) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL16967451 0.87 TP53 (0.55) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL5840884 0.87 TP53 (0.55) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL15514084 0.87 TP53 (0.55) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL8831093 0.85 POLB (0.60) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL7582210 0.84 TP53 (0.55) POLBLMNAKMT2AL3MBTL1NT5E
SCHEMBL5428265 0.84 SSTR5 (0.47) POLBLMNAKMT2AL3MBTL1SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058888-A1 Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides ALCHEMIA PTY LTD. (AU) 2004-03-25 — — US disclosed
EP-1257558-A1 METHODS FOR SYNTHESIS OF ALPHA-D-GAL (1- 3) GAL-CONTAINING OLIGOSACCHARIDES Alchemia Pty Ltd (AU) 2002-11-20 — — EP disclosed
WO-2001051499-A1 METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES ALCHEMIA PTY LTD (AU) 2001-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058888-A1 Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides B4GALT1, B3GAT3, FUT5 POLB 1325/4885LMNA 1750/4885KMT2A 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback